|
1
|
Singal A, Lampertico P and Nahon P:
Epidemiology and surveillance for hepatocellular carcinoma: New
trends. J Hepatol. 72:250–261. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lazzaro A and Hartshorn KL: A
comprehensive narrative review on the history, current landscape,
and future directions of hepatocellular carcinoma (HCC) systemic
therapy. Cancers (Basel). 15:25062023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schlosser S, Tümen D, Volz B, Neumeyer K,
Egler N, Kunst C, Tews HC, Schmid S, Kandulski A, Müller M and
Gülow K: HCC biomarkers-state of the old and outlook to future
promising biomarkers and their potential in everyday clinical
practice. Front Oncol. 12:10169522022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Omar MA, Omran MM, Farid K, Tabll AA,
Shahein YE, Emran TM, Petrovic A, Lucic NR, Smolic R, Kovac T and
Smolic M: Biomarkers for hepatocellular carcinoma: From origin to
clinical diagnosis. Biomedicines. 11:18522023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bertino G, Ardiri A, Malaguarnera M,
Malaguarnera G, Bertino N and Calvagno GS: Hepatocellualar
carcinoma serum markers. Seminars Oncol. 39:410–433. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hanif H, Ali MJ, Susheela AT, Khan IW,
Luna-Cuadros MA, Khan MM and Lau DT: Update on the applications and
limitations of alpha-fetoprotein for hepatocellular carcinoma.
World J Gastroenterol. 28:216–229. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nemeth K, Bayraktar R, Ferracin M and
Calin GA: Non-coding RNAs in disease: From mechanisms to
therapeutics. Nat Rev Genet. 25:211–232. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu SJ, Dang HX, Lim DA, Feng FY and Maher
CA: Long noncoding RNAs in cancer metastasis. Nat Rev Cancer.
21:446–460. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Verma S, Sahu BD and Mugale MN: Role of
lncRNAs in hepatocellular carcinoma. Life Sci. 325:1217512023.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ahmad M, Weiswald L, Poulain L, Denoyelle
C and Meryet-Figuiere M: Involvement of lncRNAs in cancer cells
migration, invasion and metastasis: cytoskeleton and ECM crosstalk.
J Exp Clin Cancer Res. 42:1732023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ge WJ, Huang H, Wang T, Zeng WH, Guo M,
Ren CR, Fan TY, Liu F and Zeng X: Long non-coding RNAs in
hepatocellular carcinoma. Pathol Res Pract. 248:1546042023.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wei H, Xu Z, Chen L, Wei Q, Huang Z, Liu
G, Li W, Wang J, Tang Q and Pu J: Long non-coding RNA PAARH
promotes hepatocellular carcinoma progression and angiogenesis via
upregulating HOTTIP and activating HIF-1α/VEGF signaling. Cell
Death Dis. 13:1022022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jiang B, Yang B, Wang Q, Zheng X, Guo Y
and Lu W: lncRNA PVT1 promotes hepatitis B virus-positive liver
cancer progression by disturbing histone methylation on the c-Myc
promoter. Oncol Rep. 43:718–726. 2020.PubMed/NCBI
|
|
14
|
Wang BR, Chu DX, Cheng MY, Jin Y, Luo HG
and Li N: Progress of HOTAIR-microRNA in hepatocellular carcinoma.
Hered Cancer Clin Pract. 20:42022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen T: Circulating non-coding RNAs as
potential diagnostic biomarkers in hepatocellular carcinoma. J
Hepatocell Carcinoma. 9:1029–1040. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Peng Y, Huang X and Wang H: Serum lncRNA
LINC01535 as biomarker of diagnosis, prognosis, and disease
progression in breast cancer. Clin Breast Cancer. 23:620–627. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bao H, Jiang Y, Wang N, Su H and Han X:
Long noncoding RNAs MALAT1 and HOTTIP Act as serum biomarkers for
hepatocellular carcinoma. Cancer Control. 31:107327482412848212024.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cao SW, Huang JL, Chen J, Hu YW, Hu XM,
Ren TY, Zheng SH, Lin JD, Tang J, Zheng L and Wang Q: Long
non-coding RNA UBE2CP3 promotes tumor metastasis by inducing
epithelial-mesenchymal transition in hepatocellular carcinoma.
Oncotarget. 8:65370–65385. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tripathi SK, Pal A, Ghosh S, Goel A,
Aggarwal R, Banerjee S and Das S: LncRNA NEAT1 regulates
HCV-induced hepatocellular carcinoma by modulating the miR-9-BGH3
axis. J Gen Virol. 103:2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zheng Y, Wang Y, Liu Y, Xie L, Ge J, Yu G
and Zhao G: N6-methyladenosine modification of PTTG3P contributes
to colorectal cancer proliferation via YAP1. Front Oncol.
11:6697312021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu W, Tang J, Zhang H, Kong F, Zhu H, Li
P, Li Z, Kong X and Wang K: A novel lncRNA
PTTG3P/miR-132/212-3p/FoxM1 feedback loop facilitates tumorigenesis
and metastasis of pancreatic cancer. Cell Death Discov. 6:1362020.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lu Y, Wang D, Chen G, Shan Z and Li D:
Exploring the molecular landscape of osteosarcoma through PTTG
family genes using a detailed multi-level methodology. Front Genet.
15:14316682024. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang HT, Xu YM, Ding SG, Yu XQ, Wang F,
Wang HF, Tian X and Zhong CJ: The novel lncRNA PTTG3P is
downregulated and predicts poor prognosis in non-small cell lung
cancer. Arch Med Sci. 16:931–940. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang JL, Cao SW, Ou QS, Yang B, Zheng SH,
Tang J, Chen J, Hu YW, Zheng L and Wang Q: The long non-coding RNA
PTTG3P promotes cell growth and metastasis via up-regulating PTTG1
and activating PI3K/AKT signaling in hepatocellular carcinoma. Mol
Cancer. 17:932018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang J, Zheng Y, Xiao X, Liu C, Lin J,
Zheng S, Yang B and Ou Q: A circulating long noncoding RNA panel
serves as a diagnostic marker for hepatocellular carcinoma. Dis
Markers. 2020:54175982020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tien S, Zhou H, Zhou Q, Liu H, Wu B and
Guo Y: PTTG1 alleviates acute alcoholic liver injury by inhibiting
endoplasmic reticulum stress-induced hepatocyte pyroptosis. Liver
Int. 43:840–854. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Heathcote EJ: Management of primary
biliary cirrhosis. The American association for the study of liver
diseases practice guidelines. Hepatology. 31:1005–1013. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
European Association for the Study of the
Liver. Electronic address, . simpleeasloffice@easloffice.eu;
European Association for the Study of the Liver: EASL 2017 clinical
practice guidelines on the management of hepatitis B virus
infection. J Hepatol. 67:370–398. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kolde RJR: Pheatmap: Pretty heatmaps. R
package version. 61:9152012.
|
|
31
|
Heagerty PJ, Lumley T and Pepe MS:
Time-dependent ROC curves for censored survival data and a
diagnostic marker. Biometrics. 56:337–344. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang Z, Lin E, Zhuang H, Xie L, Feng X,
Liu J and Yu Y: Construction of a novel gene-based model for
prognosis prediction of clear cell renal cell carcinoma. Cancer
Cell Int. 20:272020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Edmondson HA and Steiner PE: Primary
carcinoma of the liver: A study of 100 cases among 48,900
necropsies. Cancer. 7:462–503. 1954. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gaber DA, Shaker O, Younis AT and
El-Kassas M: LncRNA HULC and miR-122 expression pattern in
HCC-related HCV Egyptian patients. Genes (Basel). 13:16692022.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ismail M, Fadul MM, Taha R, Siddig O,
Elhafiz M, Yousef BA, Jiang Z, Zhang L and Sun L: Dynamic role of
exosomal long non-coding RNA in liver diseases: Pathogenesis and
diagnostic aspects. Hepatol Int. Sep 21–2024.(Epub ahead of print).
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Han Y, Jiang W, Wang Y, Zhao M, Li Y and
Ren L: Serum long non-coding RNA SCARNA10 serves as a potential
diagnostic biomarker for hepatocellular carcinoma. BMC Cancer.
22:4312022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang L, Niu H, Yang P, Ma J, Yuan BY,
Zeng ZC and Xiang ZL: Serum lnc34a is a potential prediction
biomarker for bone metastasis in hepatocellular carcinoma patients.
BMC Cancer. 21:1612021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu N, Dou L and Zhang X: LncRNA PTTG3P
sponge absorbs microRNA-155-5P to promote metastasis of colorectal
cancer. Onco Targets Ther. 13:5283–5291. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Long L, Gao J and Zhang R: PTTG1 enhances
oncolytic adenovirus 5 entry into pancreatic adenocarcinoma cells
by increasing CXADR expression. Viruses. 15:11532023. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen Z, Cao K, Hou Y, Lu F, Li L, Wang L,
Xia Y, Zhang L, Chen H, Li R, et al: PTTG1 knockdown enhances
radiation-induced antitumour immunity in lung adenocarcinoma. Life
Sci. 277:1195942021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Huang S, Liao Q, Li W, Deng G, Jia M, Fang
Q, Ji H and Meng M: The lncRNA PTTG3P promotes the progression of
CRPC via upregulating PTTG1. Bull Cancer. 108:359–368. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Guo XC, Li L, Gao ZH, Zhou HW, Li J and
Wang QQ: The long non-coding RNA PTTG3P promotes growth and
metastasis of cervical cancer through PTTG1. Aging (Albany NY).
11:1333–1341. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang Z and Shi Z: The pseudogene PTTG3P
promotes cell migration and invasion in esophageal squamous cell
carcinoma. Open Med (Wars). 14:516–522. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Du S, Zhang X, Jia Y, Peng P, Kong Q,
Jiang S, Li Y, Li C, Ding Z and Liu L: Hepatocyte HSPA12A inhibits
macrophage chemotaxis and activation to attenuate liver
ischemia/reperfusion injury via suppressing glycolysis-mediated
HMGB1 lactylation and secretion of hepatocytes. Theranostics.
13:3856–3871. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Maqsood Q, Sumrin A, Iqbal M, Younas S,
Hussain N, Mahnoor M and Wajid A: Hepatitis C virus/hepatitis B
virus coinfection: Current prospectives. Antivir Ther.
28:135965352311896432023. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Casadei-Gardini A, Rimini M, Kudo M,
Shimose S, Tada T, Suda G, Goh MJ, Jefremow A, Scartozzi M, Cabibbo
G, et al: Real life study of lenvatinib therapy for hepatocellular
carcinoma: RELEVANT study. Liver Cancer. 11:527–539. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kaewdech A, Sripongpun P, Assawasuwannakit
S, Wetwittayakhlang P, Jandee S, Chamroonkul N and Piratvisuth T:
FAIL-T (AFP, AST, tumor sIze, ALT, and tumor number): A model to
predict intermediate-stage HCC patients who are not good candidates
for TACE. Front Med (Lausanne). 10:10778422023. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Johnson P, Zhou Q, Dao DY and Lo YMD:
Circulating biomarkers in the diagnosis and management of
hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol.
19:670–681. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hu X, Chen R, Wei Q and Xu X: The
landscape of alpha fetoprotein in hepatocellular carcinoma: Where
are we? Int J Biol Sci. 18:536–551. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Tian S, Chen Y, Zhang Y and Xu X: Clinical
value of serum AFP and PIVKA-II for diagnosis, treatment and
prognosis of hepatocellular carcinoma. J Clin Lab Anal.
37:e248232023. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang W and Wei C: Advances in the early
diagnosis of hepatocellular carcinoma. Genes Dis. 7:308–319. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lei K, Deng Z, Wang J, Wang H, Hu R, Li Y,
Wang X, Xu J, You K and Liu Z: A novel nomogram based on the
hematological prognosis risk scoring system can predict the overall
survival of patients with hepatocellular carcinoma. J Cancer Res
Clin Oncol. 149:14631–14640. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhao Z, Zhu Y, Ni X, Lin J, Li H, Zheng L,
Zhang C, Qi X, Huo H, Lou X, et al: Serum GGT/ALT ratio predicts
vascular invasion in HBV-related HCC. Cancer Cell Int. 21:5172021.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Huang CW, Wu TH, Hsu HY, Pan KT, Lee CW,
Chong SW, Huang SF, Lin SE, Yu MC and Chen SM: Reappraisal of the
role of alkaline phosphatase in hepatocellular carcinoma. J Pers
Med. 12:5182022. View Article : Google Scholar : PubMed/NCBI
|
